Estrogen Receptor Variants

Journal of Mammary Gland Biology and Neoplasia

Volumn 3, Issue 1, 1998, Pages 73-83

  Hopp, Torsten A ^a   Fuqua, Suzanne A W ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NONE   (United States)

Author keywords

ER expression; ER mRNA splice variants; ER point mutations; Transcriptional regulation

Indexed keywords

ESTROGEN RECEPTOR; ISOPROTEIN;

BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; POINT MUTATION; REVIEW; RNA SPLICING;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; POINT MUTATION; PROTEIN ISOFORMS; RECEPTORS, ESTROGEN; RNA SPLICING; TRANSCRIPTION, GENETIC;

EID: 0031597889     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018726418931     Document Type: Article

References (75)

1. R. M. Evans (1988). The steroid and thyroid hormone receptor superfamily. Science 240:889-895.
2. V. Kumar, S. Green, G. Stack, M. Berry, J.-R. Jin, and P. Chambon (1987). Functional domains of the estrogen receptor. Cell 51:941-951.
3. V. Kumar and P. Chambon (1988). The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55:145-156.
4. G. A. Blobel, C. A. Sieff, and S. H. Orkin (1995). Ligand-dependent repression of the erythoid transcrition factor GATA-1 by the estrogen receptor. Mol. Cell. Biol. 15:3147-3153.
5. M. G. Elgort, A. Zou, K. B. Marschke, and E. A. Allegretto (1996). Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor α1 promoter via a novel sequence. Mol. Endocrinol. 10:477-487.
6. B. Stein and M. X. Yang (1995). Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kB and C/ EBPβ. Mol. Cell. Biol. 15:4971-4979.
7. P. Webb, G. N. Lopez, R. M. Uht, and P. J. Kushner (1995). Tamoxifen activation of the estrogen receptor / AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 9:443-456.
8. M. T. Tzukerman, A. Esty, D. Santiso-Mere, P. Danielian, M. G. Parker, R. B. Stein, J. W. Pike, and D. P. McDonnell (1994). Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two distinct intramolecular regions. Mol. Endocrinol. 8:21-30.
9. B. Pierrat, D. M. Heery, P. Chambon, and R. Losson (1994). A highy conserved region in the hormone-binding domain of the human estrogen receptor functions as an efficient transactivation domain in yeast. Gene 143:193-200.
10. J. D. Norris, D. Fan, S. A. Kerner, and D. P. McDonnell (1997). Identification of a third autonomous activation domain within the human estrogen receptor. Mol. Endocrinol. 11(6):747-754.
11. K. B. Horwitz, T. A. Jackson, D. L. Bain, J. K. Richter, J. S. Takimoto, and L. Tung (1996). Nuclear receptor coactivator and corepressor. Mol. Endocrinol. 10:1167-1677.
12. C. L. Smith, Z. Nawaz, and B. O'Malley (1997). Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11:657-666.
13. T. A. Jackson, J. K. Richer, D. L. Bain, G. S. Takimoto, L. Tung, and K. B. Horwitz (1997). The partial agonist activity of the antagonist-occupied steroid receptor is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressor N-COR or SMRT. Mol. Endocrinol. 11:693-705.
14. O. W. Petersen, P. E. Høyer, and B. van Deurs (1987). Frequency and distribution of estrogen receptor-positive cells in normal, nonlacting human cells. Cancer Res. 47:5748-5751.
15. C. K. Osborne (1991). Receptors. In J. R. Harris, S. Hellman, I. C. Henderson, D. W. Kinne (eds.), Breast Diseases, J. B. Lippincott, Philadelphia, pp. 301-325.
16. S. R. D. Johnston, G. Saccani-Jotti, I. E. Smith, J. Salter, J. Newby, M. Coppen, S. R. Ebbs, and M. Dowsett (1995). Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res. 55:3331-3338.
17. D. Ricketts, L. Tirnbull, G. Ryall, R. Bakhashi, N. S. B. Rawson, J.-C. Gazet, C. Nolan, and R. C. Coombes (1991). Estrogen and progestrone receptors in the normal female breast. Cancer Res. 51:1817-1822.
18. G. J. Netto, J. H. Cheek, N. Y. Zachariah, J. C. Romer, C. F. Lee, R. Schoenfeld, and Z. H. Chakmakjian (1989). Steroid receptors in benign mastectomy tissue. Am. J. Clin. Pathol. 94:14-17.
19. J. C. Allegra, M. E. Lippman, L. Green, A. Barlock, R. Simon, E. B. Thompson, K. F. Huff, and W. Griffin (1979). Estrogen receptor in patients with benign disease. Cancer 44:228-231.
20. T. van Agthoven, M. Timmermans, J. A. Foekens, L. C. J. Dorssers, and S. C. Henzen-Logmans (1994). Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign and malignant human breast tissues using dual staining immunohistoch emistry. Am. J. Clin. Pathol. 144:1238-1246.
21. J. L. Jacquemier, P. H. Rolland, D. Vague, R. Lieutaud, J. M. Spitalier, and P. M. Martin (1982). Relationships between steroid receptor and epithelial cell proliferation in benign fibrocystic disease of the breast. Cancer 49:2534-2536.
22. S. A. Khan, M. A. M. Rogers, and A. Tamsen (1994). Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res. 54:993-997.
23. S. J. Schnitt and J. L. Connolly (1996). Pathology of benign breast disorders. In J. R. Harris, M. E. Lippman, M. Morrow, S. Hellman (eds.), Diseases of the breast, Lippincott-Raven, Philadelphia, pp. 27-41.
24. S. J. London, J. L. Connolly, S. J. Schnitt, and G. A. Coldlitz (1992). A prospective study of benign breast disease and the risk of breast cancer. JAMA 267:941-944.
25. W. D. Dupont, F. F. Parl, W. H. Hartemenn, L. A. Brinton, A. C. Winfield, J. A. Worrell, P. A. Schuyler, and W. D. Plummer (1993). Breast cancer risk associated with proliferative disease and atypical hyperplasia. Cancer 71:1258-1265.
26. C. A. Bodian, K. H. Perzin, R. Lattes, P. Hoffman, and T. G. Abernathy (1993). Prognistic significance of benign proliferative breast disease. Cancer 71:3896-3897.
27. P. O'Connell, V. Pekkel, S. Fuqua, C. K. Osborne, and D. C. Allred (1994). Molecular genetic studies of early breast cancer evolution. Breast Cancer Res. Treat. 32:5-12.
28. R. F. Chuaqui, Z. Zhuang, M. R. Emmert-Buck, L. A. Liotta, and M. J. Merino (1997). Analysis of Loss of heterozygosity on chromosome 11q13 in atypical ductual hyperplasia and in situ carcinoma of the breast. Am. J. Pathol. 150:297-303.
29. S. R. Lakhani, N. Collins, M. R. Stratton, J. P. Sloane (1995). Atypical ductual hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J. Clin. Pathol. 48:611-615.
30. K. Grandien (1996). Determination of the transcription start sites in the human estrogen receptor gene and identification of a novel, tissue-specific, estrogen receptor-mRNA isoform. Mol. Cell. Endocrinol. 116:207-221.
31. K. Grandien, M. Bäckdahl, O. Ljunggren, J.-Å. Gustafsson, and A. Berkenstam (1995). Estrogen target tissue determines alternative promoter utilization of the human estrogen receptor gene in osteoblasts, and tumor cell lines. Endocrinology 136:2223-2229.
32. R. J. Weigel, D. L. Crooks, J. D. Iglehart, and E. C. DeConinck (1995). Quantitative analysis of the transcriptional start sites of estrogen receptor in breast carcinoma. Cell Growth Diff. 6:707-711.
33. L. Cicatiello, G. Cobellis, R. Addeo, M. Papa, L. Altucci, V. Sica, F. Bresciani, M. LeMeur, V. L. Kumar, P. Chambon, and A. Weisz (1995). In vivo functional analysis of the mouse estrogen receptor gene promoter: a transgenic mouse model to study tissue-specific and development al regulation of the estrogen receptor gene transcription. Mol. Endocrinol. 9(8): 1077-1090.
34. S. Hayashi, K. Imai, K. Suga, T. Kurihara, Y. Higashi, and K. Nakachi (1997). Two promoters in expression of estrogen receptor messsenger RNA in human breast cancer. Carcinogenis 18(3):459-464.
35. E. C. DeConinck, L. A. McPherson, and R. J. Weigel (1995). Transcriptional regulation of estrogen receptor in breast carcinomas. Mol. Cell. Biol. 15(4):2191-2196.
36. L. A. McPherson, V. R. Baichwal, and R. J. Weigel (1997). Identification of ERF-1 as a member of the AP-2 transcription factor family. Proc. Natl. Acad. Sci. USA 94(9):4342-4347.
37. Z. Tang, I. Treilleux, and M. Brown (1997). A transcriptional enhancer required for the differential expression of the human estrogen receptor in breast cancer. Mol. Cell. Biol. 17(3):1274-1280.
38. M. Saceda, M. E. Lippman, P. Chambon, R. L. Lindsey, M. Ponlikitmongkol, M. Puente, and M. B. Martin (1988). Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol. Endocrinol. 2:1157-1162.
39. C. G. Castles, S. Oesterreich, R. Hansen, and S. A. W. Fuqua (1997). Auto-regulation of the estrogen receptor promoter. J. Steroid Biochem. Mol. Biol 62:155-163.
40. M. P. Gaub, M. Bellard, I. Scheuer, P. Chambon, and P. Sassone Corsi (1990). Activation of the ovalbumin gene by the estrogen receptor involves the fosjun complex. Cell 63:1267-1276.
41. R. J. Weigel and E. C. deConinck (1993). Transcriptional control of the estrogen receptor in estrogen receptor-negative breast carcinoma. Cancer Res. 53:3472-3474.
42. P. J. Barrett-Lee, M. T. Travers, R. A. McClelland, Y. Luqmani, and R. C. Coombes (1987). Characterization of estrogen receptor messenger RNA in human breast cancer. Cancer Res. 47:6653-6659.
43. N. Roodi, R. Bailey, W. Kao, C. S. Verrier, C. J. Yee, W. D. Dupont, and F. F. Parl (1995). Estrogen receptor gene analysis in estrogen-receptor-positive and receptor-negative primary breast cancer. J. Natl. Cancer Inst. 87:446-451.
44. Y. L. Ottaviano, J. P. Issa, F. F. Parl, H. S. Smith, S. B. Baylin, and N. E. Davidson (1994). Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54:2552-2555.
45. A. T. Ferguson, R. G. Lapidus, S. B. Baylin, and N. E. Davidson (1995). Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. 55:2279-2283.
46. R. G. Lapidus, S. J. Nass, and N. E. Davidson (1998). The loss of estrogen and progesterone receptor gene expression in human breast cancer, J. Mam. Gland Biol. Neoplasia 3: 85-94.
47. U. Pfeffer, E. Fecarotta, and G. Vidali (1995). Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res. 55:2158-2165.
48. L. W. Rice, A. A. Jazaeri, and M. A. Shupnik (1997). Estrogen receptor mRNA splice variants in pre- and postmenopausal human endometrium and endometrial carcinoma. Gynecol. Oncol. 65:149-157.
49. S. S. Chaidarun, A. Klibanski, and J. M. Alexander (1997). Tumor-specific expression of alternatively spliced estrogen receptor messenger ribonucleic acid variants in human pituitary adenomas. J. Clin. Endocrinol. Metabol. 82:1058-1065.
50. Q. Zhang, S. G. Hilsenbeck, S. A. W. Fuqua, and Å. Borg (1996). Multiple splicing variants of the estrogen receptor are present in individual human breast tumor. J. Steroid Biochem. Mol. Biol. 59:251-260.
51. D. M. Ignar-Trowbridge, M. Pimentel, M. G. Parker, J. A. Lachlan, and K. S. Korach (1996). Peptide growth factor crosstalk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinol 137:1735-1744.
52. C. Ambrosino, L. Cicatiello, and G. Cobellis (1993). Functional antagonism between the estrogen receptor and Fos on the regulation of c-fos protooncogene transcription. Mol. Endocrinol. 7:1472-1483.
53. E. R. Leygue, P. H. Watson, and L. C. Murphy (1996). Estrogen receptor variants in normal human mammary tissue. J. Natl. Cancer Inst. 88:284-290.
54. M. W. Madsen, B. E. Reiter, S. S. Larsen, P. Briand, and A. E. Lykkesfeldt (1997). Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res. 57:585-589.
55. Y. Wang and R. J. Miksicek (1991). Identification of adominant negative form of the human estrogen receptor. Mol. Endocrinol. 5:1707-1775.
56. S. G. A. Koehorst, J. J. Cox, G. H. Donker, S. Lopes da Silva, J. P. H. Burbach, J. H. H. Thijssen, and M. A. Blankenstein (1994). Functional analysis of an alternativeliy spliced estrogen receptor lacking exon 4 isolated from MCF-7 breast cancer cells and meningioma tissue. Mol. Cell. Endocrinol. 101:237-245.
57. E. Leygue, A. Huang, L. C. Murphy, and P. H. Watson (1996). Prevalence of the estrogen receptor variant messenger RNAs in human breast cancer. Cancer Res. 56:4324-4327.
58. S. A. W. Fuqua, S. D. Fitzgerald, G. C. Chamness, A. K. Tandon, D. P. McDonnell, Z. Nawaz, and B. W. O'Malley (1991). A variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 51:105-109.
59. U. Pfeffer, E. Fecarotta, G. Arena, A. Forlani, and G. Vidali (1996). Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tisuue and cell lines. J. Steroid Biochem. Mol. Biol. 56:99-105.
60. S. A. W. Fuqua, S. D. Fitzgerald, D. C. Allred, R. M. Elledge, Z. Nawaz, D. P. McDonnell, B. W. O'Malley, G. L. Greene, and W. L. McGuire (1992). Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res. 52:483-486.
61. L. C. Murphy, M. Wang, A. Coutt, and H. Dotzlaw (1996). Novel mutations in the estrogen receptor messenger RNA in human breast cancer. H. Clin. Endocrinol. Metabol. 81:1420-1427.
62. C. G. Castles, S. A. W. Fuqua, D. M. Klotz, and S. M. Hill (1993). Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res. 53:5934-5939.
63. A. J. Desai, Y. A. Luqmani, J. E. Walters, R. C. Coope, B. Dagg, J. J. Gomm, P. E. Pace, C. N. Rees, V. Thirunavukkaras u, S. Shousha, N. P. Groome, R. Coombes, And S. Ali (1997). Presence of exon 5-deleted oestrogen receptor in human breast cancer: functional analysis and clinical significance. Brit. J. Cancer 75:1173-1184.
64. A. Huang, E. R. Leygue, L. Snell, L. C. Murphy, and P. H. Watson (1997). Expression of estrogen receptor variant messenger RNAs and determination of estrogen receptor status in human breast cancer. Am. J. Pathol. 150(5):1827-1833.
65. T. Garcia, M. Sanchez, J. L. Cox, P. A. Shaw, J. B. A. Ross, S. Lehrer, and B. Schachter (1989). Identification of a variant of the human estrogen receptor with an amino acid replacement.. Nucleic Acid Res. 17:8364.
66. P. S. Karnik, S. Kulkarni, X.-P. Liu, G. T. Budd, and R. M. Bukowski (1994). Estrogen receptor mutations in tamoxifen-resistent breast cancer. Cancer Res. 54:349-353.
67. H. Iwase, J. M. Greenman, D. M. Barnes, S. Hodgson, L. Bobrow, and C. G. Mathew (1996). Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and prosterone receptor positive tumors. Cancer Lett. 108:179-184.
68. Q.-X. Zhang, Å. Borg, D. M. Wolf, S. Oesterreich, and S. A. W. Fuqua (1997). An estrogen receptor mutant with strong hormone-independent activity from a metastic breast cancer. Cancer Res. 57:1244-1249.
69. S. F. Arnold, J. D. Obourn, H. Jaffe, and A. C. Notides (1995). Phosphorylation of the human estrogen receptor on the tyrosine 537 in vivo and by the src family tyrosine kinases in vitro. Mol. Endocrinol 9:24-33.
70. G. Castoria, A. Migliaccio, S. Green, M. Di Domenico, P. Chambon, and F. Auricchio (1993). Properties of a purified estradiol-dependent calf uterus tyrosine kinase. Biochemistry 32:1740-1750.
71. M. F. Kohler, A. Berkholz, J. I. Risinger, A. Elbendary, J. Boyd, and A. Berchuck (1995). Mutational analysis of the estrogen-receptor gene in endometrial carcinoma. Obstet. Gynecol. 86:33-37.
72. K. E. Weis, K. Ekena, J. A. Thomas, G. Lazennec, and B. S. Katzenellenbogen (1996). Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol. Endocrinol. 10(11):1388-1398.
73. G. G. J. M. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, J.-Å. Gustafsson (1996). Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 93:5925.
74. C. Hu, S. M. Hyder, D. S. Needleman, and V. V. Baker (1996). Expression of the estrogen receptor variants in normal and neoplastic human uterus. Mol. Cell. Endocrinol. 118:173-179.
75. K. Paech, P. Webb, G. G. J. M. Kuiper, S. Nilsson, J.-Å. Gustafsson, P. J. Kushner, and T. S. Scanlan (1997). Differential ligand activation of estrogen receptor ERα and ERβ at AP-1 sites. Science 277:1508-1510.